Skip to main content

Advertisement

SpringerLink
Log in

Beta-blockers in heart failure: Is more better?

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Therapies that modulate the sympathetic nervous system and renin-angiotensin-aldosterone system reduce morbidity and mortality in patients with heart failure. However, they are grossly underused in clinical practice; when used, the doses prescribed are substantially smaller than the target doses used in the large-scale studies that established their utility. Whether these suboptimal doses are as effective in reducing morbidity and mortality is largely unknown. This review focuses on the relationship between the dose of β-blockers and their effect on clinical outcomes. Because direct dose comparisons of β-blockers are limited, we draw upon a broader spectrum of clinical trials across the cardiovascular continuum that involved neurohormonal modulators to address the question, ‘Is more better?’

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429–1435.

  2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293–302.

  3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327:685-691. [Published erratum appears in N Engl J Med 1992, 327:1768.]

  4. Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670–1676.

    Article  PubMed  CAS  Google Scholar 

  5. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  6. Torp-Pedersen C, Kober L: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999, 354:9–12.

    Article  PubMed  CAS  Google Scholar 

  7. Packer M, Fowler MB, Roecker EB, et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194–2199.

    Article  PubMed  Google Scholar 

  8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13.

  9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001–2007.

  10. Buhler FR, Laragh JH, Baer L, et al.: Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972, 287:1209–1214.

    Article  PubMed  CAS  Google Scholar 

  11. Roe CM, Motheral BR, Teitelbaum F, Rich MW: Angiotensinconverting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 1999, 138:818–825.

    Article  PubMed  CAS  Google Scholar 

  12. dep ME, Shah NB, Tateo IM, Massie BM: Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997, 30:518–526.

    Article  Google Scholar 

  13. Philbin EF, Andreaou C, Rocco TA, et al.: Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996, 77:832–838.

    Article  PubMed  CAS  Google Scholar 

  14. Mendelson G, Aronow WS: Underutilization of angiotensinconverting enzyme inhibitors in older patients with Q-wave anterior myocardial infarction in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1998, 46:751–752.

    PubMed  CAS  Google Scholar 

  15. Bristow MR, Gilbert EM, Abraham WT, et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996, 94:2807–2816.

    PubMed  CAS  Google Scholar 

  16. Bristow MR, O’Connell JB, Gilbert EM, et al.: Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic or dilated or ischemic cardiomyopathy. Circulation 1994, 89:1632–1642.

    PubMed  CAS  Google Scholar 

  17. Simon T, Mary-Krause M, Funck-Brentano C, et al.: Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003, 24:552–559. This retrospective analysis of the CIBIS II trial highlights the importance of dose on prognosis in patients with heart failure.

    Article  PubMed  CAS  Google Scholar 

  18. Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100:2312–2318.

    PubMed  CAS  Google Scholar 

  19. Baruch L, Anand I, Cohen IS, et al.: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999, 99:2658–2664.

    PubMed  CAS  Google Scholar 

  20. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. This prospective study suggests that higher doses of an ARB confer greater nephroprotection despite similar levels of blood pressure control.

    Article  PubMed  CAS  Google Scholar 

  21. Lonn E, Yusuf S, Dzavik V, et al.: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103:919–925.

    PubMed  CAS  Google Scholar 

  22. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  23. Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752–760.

    Article  PubMed  CAS  Google Scholar 

  24. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  25. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.

    Article  PubMed  CAS  Google Scholar 

  27. Dickstein K: What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? Am Heart J 2003, 145:754–757.

    Article  PubMed  Google Scholar 

  28. Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7–13.

    Article  PubMed  CAS  Google Scholar 

  29. Kukin ML, Kalman J, Charney RH, et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99:2645–2651.

    PubMed  CAS  Google Scholar 

  30. Kukin ML, Mannino MM, Freudenberger RS, et al.: Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 2000, 35:45–50.

    Article  PubMed  CAS  Google Scholar 

  31. Metra M, Giubbini R, Nodari S, et al.: Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000, 102:546–551.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bronx VA Medical Center, 130 West Kingsbridge Road, 10468, Bronx, NY, USA

    Lawrence Baruch MD

Authors
  1. Lawrence Baruch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prabhakara Kunamneni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baruch, L., Kunamneni, P. Beta-blockers in heart failure: Is more better?. Curr Heart Fail Rep 1, 77–81 (2004). https://doi.org/10.1007/s11897-004-0030-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-004-0030-7

Keywords

Search

Navigation